NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Endeavor BioMedicines

Endeavor BioMedicines

Private
San Diego, CaliforniaHealthcare & Life Scienceshttps://endeavorbiomedicines.com/

Last Round

Series C

Apr 24, 2024

Total Funding Raised

$295.5M

Company Overview

Endeavor BioMedicines is a biotechnology company that develops precision medicines targeting the underlying genetic and cellular causes of life-threatening diseases such as pulmonary fibrosis and cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologyclinical-stage biotechprecision medicinedrug discoveryfibrotic diseasesidiopathic pulmonary fibrosisIPFsmall molecule inhibitorhedgehog signaling pathwayoncologyclinical trialsdrug pipelinebiopharmatherapeutic candidatesventure-backed biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Endeavor BioMedicines Comps

Public and private peers based on sector, stage, and business model.

Endeavor BioMedicines comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Endeavor BioMedicines Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CApr 24, 2024
Series BFeb 7, 2022
Series AJan 7, 2021

Key People

Founding team and executive leadership

Vishaal Turakhia

Chief Financial Officer

Executive Team

Chris Krueger

Chief Operating Officer

Executive Team

Endeavor BioMedicines Investors

Notable investors and investment history

Endeavor BioMedicines investors
InvestorRounds
Longitude CapitalSeries C, Series B, Series A
Aberdeen Group plcSeries C
SymBiosis Capital ManagementSeries C
Omega FundsSeries C, Series B, Series A
EckuitySeries C
Perceptive AdvisorsSeries C, Series B
abrdn Inc.Series C

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 1, 2025

    Two posters accepted for American Thoracic Society 2025 International Conference.

  • Apr 2, 2025

    Lisa Lancaster, M.D. appointed as new Chief Medical Officer.

Endeavor BioMedicines Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Endeavor BioMedicines Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Endeavor BioMedicines's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Diego, California
Employee Range51
Year Founded2019
Last FundingApr 24, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.